Lisa M. Raven MBBS, FRACP , Jerry R. Greenfield MBBS (Hons 1), PhD, FRACP , Andrew Jabbour BSc (Med), MBBS (Hons), PhD, FRACP , Peter S. Macdonald MBBS, MD, PhD, FRACP , Christopher A. Muir MBBS (Hons), FRACP, PhD
{"title":"钠葡萄糖共转运蛋白2抑制剂与心脏移植肾稳定有关","authors":"Lisa M. Raven MBBS, FRACP , Jerry R. Greenfield MBBS (Hons 1), PhD, FRACP , Andrew Jabbour BSc (Med), MBBS (Hons), PhD, FRACP , Peter S. Macdonald MBBS, MD, PhD, FRACP , Christopher A. Muir MBBS (Hons), FRACP, PhD","doi":"10.1016/j.jhlto.2025.100255","DOIUrl":null,"url":null,"abstract":"<div><div>Sodium glucose cotransporter 2 inhibitors (SGLT2i) are standard of care for type 2 diabetes mellitus, heart failure, and chronic kidney disease (CKD). Heart transplant (HTx) recipients are at increased risk of diabetes and CKD, and both are independently associated with increased mortality. In a retrospective analysis of 104 HTx recipients with diabetes (23 exposed to SGLT2i, 81 not exposed), SGLT2i treatment was associated with stable renal function at 3 years post-HTx, measured by estimated glomerular filtration rate change from baseline (median change of 0 ml/min/1.73 m<sup>2</sup> (interquartile range [IQR] −13 to +11)), compared to a change of −15 ml/min/1.73 m<sup>2</sup> (IQR −27 to +1) in patients not exposed to SGLT2i (<em>p</em> = 0.02). There was no significant difference in survival by SGLT2i exposure, adjusted for diabetes type and baseline creatinine (hazard ratio 0.34, confidence intervals 0.11-1.06, <em>p</em> = 0.06). Further investigation of SGLT2i in HTx recipients, particularly focusing on renal outcomes, is required.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"8 ","pages":"Article 100255"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sodium glucose cotransporter 2 inhibitors are associated with renal stabilization in heart transplantation\",\"authors\":\"Lisa M. Raven MBBS, FRACP , Jerry R. Greenfield MBBS (Hons 1), PhD, FRACP , Andrew Jabbour BSc (Med), MBBS (Hons), PhD, FRACP , Peter S. Macdonald MBBS, MD, PhD, FRACP , Christopher A. Muir MBBS (Hons), FRACP, PhD\",\"doi\":\"10.1016/j.jhlto.2025.100255\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Sodium glucose cotransporter 2 inhibitors (SGLT2i) are standard of care for type 2 diabetes mellitus, heart failure, and chronic kidney disease (CKD). Heart transplant (HTx) recipients are at increased risk of diabetes and CKD, and both are independently associated with increased mortality. In a retrospective analysis of 104 HTx recipients with diabetes (23 exposed to SGLT2i, 81 not exposed), SGLT2i treatment was associated with stable renal function at 3 years post-HTx, measured by estimated glomerular filtration rate change from baseline (median change of 0 ml/min/1.73 m<sup>2</sup> (interquartile range [IQR] −13 to +11)), compared to a change of −15 ml/min/1.73 m<sup>2</sup> (IQR −27 to +1) in patients not exposed to SGLT2i (<em>p</em> = 0.02). There was no significant difference in survival by SGLT2i exposure, adjusted for diabetes type and baseline creatinine (hazard ratio 0.34, confidence intervals 0.11-1.06, <em>p</em> = 0.06). Further investigation of SGLT2i in HTx recipients, particularly focusing on renal outcomes, is required.</div></div>\",\"PeriodicalId\":100741,\"journal\":{\"name\":\"JHLT Open\",\"volume\":\"8 \",\"pages\":\"Article 100255\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JHLT Open\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2950133425000503\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JHLT Open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2950133425000503","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Sodium glucose cotransporter 2 inhibitors are associated with renal stabilization in heart transplantation
Sodium glucose cotransporter 2 inhibitors (SGLT2i) are standard of care for type 2 diabetes mellitus, heart failure, and chronic kidney disease (CKD). Heart transplant (HTx) recipients are at increased risk of diabetes and CKD, and both are independently associated with increased mortality. In a retrospective analysis of 104 HTx recipients with diabetes (23 exposed to SGLT2i, 81 not exposed), SGLT2i treatment was associated with stable renal function at 3 years post-HTx, measured by estimated glomerular filtration rate change from baseline (median change of 0 ml/min/1.73 m2 (interquartile range [IQR] −13 to +11)), compared to a change of −15 ml/min/1.73 m2 (IQR −27 to +1) in patients not exposed to SGLT2i (p = 0.02). There was no significant difference in survival by SGLT2i exposure, adjusted for diabetes type and baseline creatinine (hazard ratio 0.34, confidence intervals 0.11-1.06, p = 0.06). Further investigation of SGLT2i in HTx recipients, particularly focusing on renal outcomes, is required.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
